{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:55:15Z","timestamp":1791125715784,"version":"4.1.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T00:00:00Z","timestamp":1393545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"},{"start":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T00:00:00Z","timestamp":1393545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1038\/leu.2014.91","type":"journal-article","created":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T07:42:40Z","timestamp":1393573360000},"page":"1388-1395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["How we manage follicular lymphoma"],"prefix":"10.1038","volume":"28","author":[{"given":"W","family":"Hiddemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B D","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,28]]},"reference":[{"key":"BFleu201491_CR1","unstructured":"National Cancer Institute. SEER Cancer Statistics Review. NIH: Bethesda, Maryland, USA, 2008; 23."},{"key":"BFleu201491_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"7","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weissenburger DD . Epidemiology of the non-Hodgki\u0144s lymphomas: distribution of the major subtypes differ by geographic locations. Non-Hodgki\u0144s Lymphoma Classification Project. Ann Oncol 1998; 7: 717\u2013720.","journal-title":"Ann Oncol"},{"key":"BFleu201491_CR3","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1172\/JCI63186","volume":"122","author":"R Kridel","year":"2012","unstructured":"Kridel R, Sehn LH, Gascoyne RD . Pathogenesis of follicular lymphoma. J Clin Invest 2012; 122: 3424\u20133431.","journal-title":"J Clin Invest"},{"key":"BFleu201491_CR4","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1182\/blood-2011-11-367730","volume":"119","author":"FK Stevenson","year":"2012","unstructured":"Stevenson FK, Stevenson GT . Follicular lymphoma and the immune system: from pathogenesis to antibody therapy. Blood 2012; 119: 3659\u20133667.","journal-title":"Blood"},{"key":"BFleu201491_CR5","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn. WHO: Geneva, Siwtzerland, 2008."},{"key":"BFleu201491_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1158\/2159-8290.CD-11-0208","volume":"2","author":"O Weigert","year":"2012","unstructured":"Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D et al. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Dis 2012; 2: 47\u201355.","journal-title":"Cancer Dis"},{"key":"BFleu201491_CR7","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1182\/blood-2012-05-414995","volume":"120","author":"O Weigert","year":"2012","unstructured":"Weigert O, Weinstock DM . The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. Blood 2012; 120: 2553\u20132561.","journal-title":"Blood"},{"key":"BFleu201491_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","volume":"8","author":"AD Zelenetz","year":"2010","unstructured":"Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010; 8: 288\u2013334.","journal-title":"J Natl Compr Canc Netw"},{"key":"BFleu201491_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/annonc\/mds517","volume":"24","author":"M Ghielmini","year":"2013","unstructured":"Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M et al. ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukaemia (CLL). Ann Oncol 2013; 24: 561\u2013576.","journal-title":"Ann Oncol"},{"key":"BFleu201491_CR10","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","volume":"14","author":"MP Mac Manus","year":"1996","unstructured":"Mac Manus MP, Hoppe RT . Is radiotherapy curative for stage I and II low-grade follicular lymphoma? results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282\u20131290.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR11","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12<2273::AID-CNCR9>3.0.CO;2-V","volume":"80","author":"M Stuschke","year":"1997","unstructured":"Stuschke M, Hoederath A, Sack H, P\u00f6tter R, M\u00fcller RP, Schulz U et al. Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-fr\u00fche Stadien. Cancer 1997; 80: 2273\u20132284.","journal-title":"Cancer"},{"key":"BFleu201491_CR12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","volume":"51","author":"RB Wilder","year":"2001","unstructured":"Wilder RB, Jones D, Tucker SL, Fuller LM, Ha CS, McLaughlin P et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51: 1219\u20131227.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFleu201491_CR13","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","volume":"64","author":"BA Guadagnolo","year":"2006","unstructured":"Guadagnolo BA, Li S, Neuberg D, Ng A, Hua L, Silver B et al. Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006; 64: 928\u2013934.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFleu201491_CR14","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.25149","volume":"116","author":"TJ Pugh","year":"2010","unstructured":"Pugh TJ, Ballonoff A, Newman F, Rabinovitch R . Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer 2010; 116: 3843\u20133851.","journal-title":"Cancer"},{"key":"BFleu201491_CR15","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1002\/cncr.25117","volume":"116","author":"BA Campbell","year":"2010","unstructured":"Campbell BA, Voss N, Woods R, Gascoyne RD, Morris J, Pickles T et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 2010; 116: 3797\u20133806.","journal-title":"Cancer"},{"key":"BFleu201491_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011; 100: 86\u201392.","journal-title":"Radiother Oncol"},{"key":"BFleu201491_CR17","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 2012; 30: 3368\u20133375.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR18","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1200\/JCO.2010.30.1622","volume":"29","author":"L Wennekes","year":"2011","unstructured":"Wennekes L, Ottevanger PB, Raemaekers JM, Schouten HC, de Kok MW, Punt CJ et al. Development and measurement of guideline-based indicators for patients with non-Hodgkin's lymphoma. J Clin Oncol 2011; 29: 1436\u20131444.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR19","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning SJ . Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454\u20131459.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR20","first-page":"a3699","volume":"118","author":"M Ruella","year":"2011","unstructured":"Ruella M, Filippi A, Di Russo A, Caracciolo D, Matteucci P, Magni M et al. Rituximab followed by involved field radiotherapy (IF-RT) in stage I-II follicular lymphoma (FL): long term results. Blood (ASH Annual Meeting Abstracts) 2011; 118: a3699.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFleu201491_CR21","first-page":"a1634","volume":"120","author":"K Herfarth","year":"2012","unstructured":"Herfarth K, Engelhard M, Borchmann P, Hohloch K, Budach V, Viardot A et al. Treatment of early stage nodal follicular lymphoma using involved-field radiotherapy and rituximab: preliminary results of the MIR trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG). Blood (ASH Annual Meeting Abstracts) 2012; 120: a1634.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFleu201491_CR22","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Ha\u00efoun C, Moreau P et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1110\u20131117.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516\u2013522.","journal-title":"Lancet"},{"key":"BFleu201491_CR24","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol 2010; 28: 4480\u20134484.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR25","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/annonc\/mds177","volume":"23","author":"P Colombat","year":"2012","unstructured":"Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol 2012; 23: 2380\u20132385.","journal-title":"Ann Oncol"},{"key":"BFleu201491_CR26","doi-asserted-by":"publisher","first-page":"a6","DOI":"10.1182\/blood.V116.21.6.6","volume":"116","author":"K Ardeshna","year":"2010","unstructured":"Ardeshna K, Qian W, Smith P, Warden J, Stevens L, Pocock CFE et al. An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood 2010; 116: a6.","journal-title":"Blood"},{"issue":"Suppl. 4","key":"BFleu201491_CR27","first-page":"a019","volume":"22","author":"K Ardeshna","year":"2011","unstructured":"Ardeshna K, Qian W, Stephens R, Smith P, Warden J, Lowry L et al. Preliminary results of quality of life analyses from the Intergroup phase III randomized trial of rituximab vs. a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma. Ann Oncol 2011; 22 (Suppl. 4): a019.","journal-title":"Ann Oncol"},{"key":"BFleu201491_CR28","doi-asserted-by":"publisher","first-page":"LBA6","DOI":"10.1182\/blood.V118.21.LBA-6.bld0076_P3_LBA-6","volume":"118","author":"BS Kahl","year":"2011","unstructured":"Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC et al. Results of the Eastern Cooperative Oncology Group protocol E 4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 2011; 118: LBA6.","journal-title":"Blood"},{"key":"BFleu201491_CR29","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1200\/JCO.2010.33.4474","volume":"30","author":"P Solal-C\u00e9ligny","year":"2012","unstructured":"Solal-C\u00e9ligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 2012; 30: 848\u2013853.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR30","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1200\/JCO.2012.43.6584","volume":"30","author":"BD Cheson","year":"2012","unstructured":"Cheson BD . Waiting is the hardest part. J Clin Oncol 2012; 30: 3781\u20133782.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR31","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725\u20133732.","journal-title":"Blood"},{"key":"BFleu201491_CR32","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417\u20131423.","journal-title":"Blood"},{"key":"BFleu201491_CR33","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986\u20131992.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR34","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","volume":"112","author":"G Salles","year":"2008","unstructured":"Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824\u20134831.","journal-title":"Blood"},{"key":"BFleu201491_CR35","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579\u20134586.","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"BFleu201491_CR36","first-page":"iv88","volume":"22","author":"F Morschhauser","year":"2011","unstructured":"Morschhauser F, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Bouabadallah R et al. Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study. Ann Oncol 2011; 22 (suppl 4): iv88.","journal-title":"Ann Oncol"},{"key":"BFleu201491_CR37","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Luminari S, Dondi A, Sacchi S, Tucci A, Vitolo U et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi (FIL). J Clin Oncol 2013; 31: 1506\u20131513.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR38","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203\u20131210.","journal-title":"Lancet"},{"key":"BFleu201491_CR39","doi-asserted-by":"publisher","first-page":"a 902","DOI":"10.1182\/blood.V120.21.902.902","volume":"120","author":"IW Flinn","year":"2012","unstructured":"Flinn IW, Van der Jagt RH, Kahl BS, Wood P, Hawkins TE et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): the Bright study. Blood 2012; 120: a 902.","journal-title":"Blood"},{"key":"BFleu201491_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441\u2013449.","journal-title":"N Engl J Med"},{"key":"BFleu201491_CR41","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","volume":"24","author":"OW Press","year":"2006","unstructured":"Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M et al. Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006; 24: 4143\u20134149.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR42","doi-asserted-by":"publisher","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","volume":"14","author":"SA Jacobs","year":"2008","unstructured":"Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008; 14: 7088\u20137094.","journal-title":"Clin Cancer Res"},{"key":"BFleu201491_CR43","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1200\/JCO.2009.27.8325","volume":"28","author":"BK Link","year":"2010","unstructured":"Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP . Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010; 28: 3035\u20133041.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR44","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156\u20135164.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR45","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","volume":"31","author":"OW Press","year":"2013","unstructured":"Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 2013; 31: 314\u2013320.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR46","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","volume":"104","author":"G Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667\u20132674.","journal-title":"Blood"},{"key":"BFleu201491_CR47","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","volume":"105","author":"E Deconinck","year":"2005","unstructured":"Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 105: 3817\u20133823.","journal-title":"Blood"},{"key":"BFleu201491_CR48","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"C Sebban","year":"2006","unstructured":"Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540\u20132544.","journal-title":"Blood"},{"key":"BFleu201491_CR49","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A et al. Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004\u20134013.","journal-title":"Blood"},{"key":"BFleu201491_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/jnci\/djr450","volume":"104","author":"M Al Khabori","year":"2012","unstructured":"Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M . Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104: 18\u201328.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201491_CR51","doi-asserted-by":"publisher","first-page":"a419","DOI":"10.1182\/blood.V122.21.419.419","volume":"223","author":"W Hiddemann","year":"2013","unstructured":"Hiddemann W, Dreyling MH, Metzner B, Pfreundschuh M, Wilhelm M et al. Evaluation of myeloablative therapy followed by autologous stem cell transplantation in first remission in patients with advanced stage follicular lymphoma after initial immuno-chemotherapy (R-CHOP) or chemotherapy alone: analysis of 940 patients treated in prospective randomized trials of the German Low Grade Lymphoma Study Group (GLSG). Blood 2013; 223: a419.","journal-title":"Blood"},{"key":"BFleu201491_CR52","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","volume":"25","author":"AZ Rohatiner","year":"2007","unstructured":"Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007; 25: 2554\u20132559.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR53","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","volume":"26","author":"C Sebban","year":"2008","unstructured":"Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N et al. Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008; 26: 3614\u20133620.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR54","doi-asserted-by":"publisher","first-page":"a 2189","DOI":"10.1182\/blood.V112.11.2189.2189","volume":"112","author":"O Weigert","year":"2008","unstructured":"Weigert O, Uysal A, Metzner B, Pfreundschuh M, Schmitz N, Wandt H et al. Impact of autologous stem cell transplantation and\/or rituximab on outcome of patients with relapsed follicular lymphoma- retrospective analysis of 2 randomized trials of the German Low Grade Lymphoma Study Group (GLSG). Blood 2008; 112: a 2189.","journal-title":"Blood"},{"key":"BFleu201491_CR55","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","volume":"96","author":"S Le Gouill","year":"2011","unstructured":"Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study. Haematologica 2011; 96: 1128\u20131135.","journal-title":"Haematologica"},{"key":"BFleu201491_CR56","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3324\/haematol.2012.069583","volume":"98","author":"S Montoto","year":"2013","unstructured":"Montoto S, Matthews J, Greaves P, Lillington D, Anderson D, Gribben JG et al. Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. Haematologica 2013; 98: 620\u2013625.","journal-title":"Haematologica"},{"key":"BFleu201491_CR57","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"JD Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris 3rd HA, Scullin Jr DC, Corso SW, Yardley DA et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261\u20134267.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR58","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416\u20134423.","journal-title":"Blood"},{"key":"BFleu201491_CR59","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH van Oers","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295\u20133301.","journal-title":"Blood"},{"key":"BFleu201491_CR60","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, B\u00f6ck HP, Repp R, Wandt H et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003\u20134008.","journal-title":"Blood"},{"key":"BFleu201491_CR61","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27: 1607\u20131614.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR62","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42\u201351.","journal-title":"Lancet"},{"key":"BFleu201491_CR63","doi-asserted-by":"publisher","first-page":"a509","DOI":"10.1182\/blood.V122.21.509.509","volume":"223","author":"G Salles","year":"2013","unstructured":"Salles G, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Blood 2013; 223: a509.","journal-title":"Blood"},{"key":"BFleu201491_CR64","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA . Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088\u20131095.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR65","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1200\/JCO.2012.44.8290","volume":"31","author":"U Vitolo","year":"2013","unstructured":"Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F et al. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol 2013; 31: 3351\u20133359.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR66","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.beha.2011.03.006","volume":"24","author":"BD Cheson","year":"2011","unstructured":"Cheson BD . New agents in follicular lymphoma. Best Pract Res Clin Haematol 2011; 24: 305\u2013312.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu201491_CR67","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrclinonc.2010.189","volume":"8","author":"A Younes","year":"2011","unstructured":"Younes A . Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011; 8: 85\u201396.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFleu201491_CR68","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","volume":"111","author":"A Hagenbeek","year":"2008","unstructured":"Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial. Blood 2008; 111: 5486\u20135495.","journal-title":"Blood"},{"key":"BFleu201491_CR69","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","volume":"119","author":"MS Czuczman","year":"2012","unstructured":"Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012; 119: 3698\u20133704.","journal-title":"Blood"},{"key":"BFleu201491_CR70","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1182\/blood-2012-02-408773","volume":"119","author":"LH Sehn","year":"2012","unstructured":"Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012; 119: 5118\u20135125.","journal-title":"Blood"},{"key":"BFleu201491_CR71","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","volume":"31","author":"G Salles","year":"2013","unstructured":"Salles G, Morschhauser F, Solal-Celigny P, Thieblemont C, Lamy T, Tilly H et al. Obinutuzumab (GA 101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGIN study. J Clin Oncol 2013; 31: 2920\u20132926.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR72","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","volume":"122","author":"J Radford","year":"2013","unstructured":"Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R et al. Obinutuzumab (GA 101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 2013; 122: 1137\u20131143.","journal-title":"Blood"},{"key":"BFleu201491_CR73","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 3880\u20133886.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR74","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1002\/cncr.28299","volume":"119","author":"BW Grant","year":"2013","unstructured":"Grant BW, Jung SH, Johnson JL, Kostakoglu L, His E, Byrd JC et al. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 2013; 119: 3797\u20133804.","journal-title":"Cancer"},{"key":"BFleu201491_CR75","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","volume":"28","author":"A Advani","year":"2010","unstructured":"Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28: 2085\u20132093.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR76","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","volume":"31","author":"L Fayad","year":"2013","unstructured":"Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 2013; 31: 573\u2013583.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR77","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1093\/annonc\/mdr620","volume":"23","author":"MS Czuczman","year":"2012","unstructured":"Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol 2012; 23: 2356\u20132362.","journal-title":"Ann Oncol"},{"key":"BFleu201491_CR78","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974\u2013977.","journal-title":"Science"},{"key":"BFleu201491_CR79","doi-asserted-by":"publisher","first-page":"a 2723","DOI":"10.1182\/blood.V114.22.2723.2723","volume":"114","author":"D Nagorsen","year":"2009","unstructured":"Nagorsen D, Zugmaier G, Viardot A, Goebeler M, Noppeney R, Schmidt M et al. Confirmation of safety, efficacy and response duration in non-Hodgkin lymphoma patients treated with 60 \u03bcg\/m2\/d of BiTE\u00ae antibody Blinatumomab. Blood 2009; 114: a 2723.","journal-title":"Blood"},{"key":"BFleu201491_CR80","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822\u20133829.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR81","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","volume":"28","author":"SM Smith","year":"2010","unstructured":"Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol 2010; 28: 4740\u20134746.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR82","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/leu.2010.226","volume":"25","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukaemia 2011; 25: 341\u2013347.","journal-title":"Leukaemia"},{"key":"BFleu201491_CR83","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","volume":"119","author":"SA Meadows","year":"2012","unstructured":"Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL et al. PI3K\u03b4 inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012; 119: 1897\u20131900.","journal-title":"Blood"},{"key":"BFleu201491_CR84","doi-asserted-by":"publisher","first-page":"a85","DOI":"10.1182\/blood.V122.21.85.85","volume":"223","author":"A Gopal","year":"2013","unstructured":"Gopal A, Kahl BS, De Vos S, Wagner-Johnston ND, Schuster SJ, Blum KA et al. Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). Blood 2013; 223: a85.","journal-title":"Blood"},{"key":"BFleu201491_CR85","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Blood 2010; 115: 2578\u20132585.","journal-title":"Blood"},{"key":"BFleu201491_CR86","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88\u201394.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR87","doi-asserted-by":"publisher","first-page":"a3943","DOI":"10.1182\/blood.V116.21.3943.3943","volume":"116","author":"B Kahl","year":"2010","unstructured":"Kahl B, Roberts AW, Seymour JF, Advani RH, Persky DO, Yang J et al. Navitoclax (ABT-263) plus rituximab: Interim results of a phase I study in patients with CD 20-positive lymphoid malignancies. Blood 2010; 116: a3943.","journal-title":"Blood"},{"key":"BFleu201491_CR88","doi-asserted-by":"publisher","first-page":"a304","DOI":"10.1182\/blood.V120.21.304.304","volume":"120","author":"MS Davids","year":"2012","unstructured":"Davids MS, Roberts AW, Anderson MA, Pagel JM, Kahl BS, Gerecitano JF et al. The bcl2 specific BH3-mimetic ABT-199 (GDC-0199) is active and well tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study. Blood 2012; 120: a304.","journal-title":"Blood"},{"key":"BFleu201491_CR89","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","volume":"26","author":"AA Chanan-Khan","year":"2008","unstructured":"Chanan-Khan AA, Cheson BD . Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26: 1544\u20131552.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR90","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","volume":"27","author":"TE Witzig","year":"2009","unstructured":"Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009; 27: 5404\u20135409.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR91","doi-asserted-by":"publisher","first-page":"a 1679","DOI":"10.1182\/blood.V114.22.1679.1679","volume":"114","author":"M Dutia","year":"2009","unstructured":"Dutia M, DeRoock I, Chee K, O'donnell R, Quirch C, Reed-Pease C et al. R2: Preliminary results of a phase II study of lenalidomide and rituximab in relapsed \/ refractory indolent Non-Hodgkin's Lymphoma (NHL). Blood 2009; 114: a 1679.","journal-title":"Blood"},{"key":"BFleu201491_CR92","doi-asserted-by":"publisher","first-page":"a 901","DOI":"10.1182\/blood.V120.21.901.901","volume":"120","author":"NH Fowler","year":"2012","unstructured":"Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE et al. Lenalidomide and rituximab for untreated indolent lymphoma: final results of a phase II study. Blood 2012; 120: a 901.","journal-title":"Blood"},{"key":"BFleu201491_CR93","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258\u20131265.","journal-title":"Blood"},{"key":"BFleu201491_CR94","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"C Buske","year":"2006","unstructured":"Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W . The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504\u20131508.","journal-title":"Blood"},{"key":"BFleu201491_CR95","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27: 4555\u20134562.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR96","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159\u20132169.","journal-title":"N Engl J Med"},{"key":"BFleu201491_CR97","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2004-06-2298","volume":"105","author":"AM Glas","year":"2005","unstructured":"Glas AM, Kersten MJ, Delahaye LJ, Witteveen AT, Kibbelaar RE, Velds A et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105: 301\u2013307.","journal-title":"Blood"},{"key":"BFleu201491_CR98","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/gcc.20617","volume":"48","author":"C Schwaenen","year":"2009","unstructured":"Schwaenen C, Viardot A, Berger H, Barth TF, Bentink S, D\u00f6hner H et al. Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer 2009; 48: 39\u201354.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFleu201491_CR99","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","volume":"115","author":"P Farinha","year":"2010","unstructured":"Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD . The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010; 115: 289\u2013295.","journal-title":"Blood"},{"key":"BFleu201491_CR100","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","volume":"29","author":"J Trotman","year":"2011","unstructured":"Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011; 29: 3194\u20133200.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR101","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol 2012; 30: 4317\u20134322.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR102","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/annonc\/mdt562","volume":"25","author":"S Luminari","year":"2014","unstructured":"Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol 2014; 25: 442\u2013447.","journal-title":"Ann Oncol"},{"key":"BFleu201491_CR103","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFleu201491_CR104","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-62703-269-8_10","volume":"971","author":"C Pott","year":"2013","unstructured":"Pott C, Br\u00fcggemann M, Ritgen M, van der Velden VH, van Dongen JJ, Kneba M . MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods Mol Biol 2013; 971: 175\u2013200.","journal-title":"Methods Mol Biol"},{"key":"BFleu201491_CR105","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","volume":"94","author":"AS Freedman","year":"1999","unstructured":"Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325\u20133333.","journal-title":"Blood"},{"key":"BFleu201491_CR106","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.V99.3.856","volume":"99","author":"A Rambaldi","year":"2002","unstructured":"Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856\u2013862.","journal-title":"Blood"},{"key":"BFleu201491_CR107","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","volume":"122","author":"M Ladetto","year":"2013","unstructured":"Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive programme. Blood 2013; 122: 3759\u20133766.","journal-title":"Blood"},{"key":"BFleu201491_CR108","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2141.2008.07101.x","volume":"141","author":"C Hirt","year":"2008","unstructured":"Hirt C, Sch\u00fcler F, Kiefer T, Schwenke C, Haas A, Niederwieser D et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol 2008; 141: 631\u2013640.","journal-title":"Br J Haematol"},{"key":"BFleu201491_CR109","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/annonc\/mdg201","volume":"14","author":"J Mangel","year":"2003","unstructured":"Mangel J, Buckstein R, Imrie K, Spaner D, Franssen E, Pavlin P et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as \u2018in vivo purge\u2019 and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol 2003; 14: 758\u2013765.","journal-title":"Ann Oncol"},{"key":"BFleu201491_CR110","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/bmt.2008.382","volume":"43","author":"LK Hicks","year":"2009","unstructured":"Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009; 43: 701\u2013708.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu201491_CR111","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1093\/annonc\/mds202","volume":"23","author":"F Morschhauser","year":"2012","unstructured":"Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P et al. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Ann Oncol 2012; 23: 2687\u20132695.","journal-title":"Ann Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201491.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201491","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201491.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T19:04:34Z","timestamp":1650308674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,28]]},"references-count":111,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["BFleu201491"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.91","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,28]]},"assertion":[{"value":"14 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WH serves as a member of the International Advisory Board of Roche AG and receives research grants from Roche for the support of clinical trials.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}